Anixa Biosciences, Inc. (ANIX): Price and Financial Metrics


Anixa Biosciences, Inc. (ANIX): $4.57

-0.24 (-4.99%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ANIX POWR Grades


  • Sentiment is the dimension where ANIX ranks best; there it ranks ahead of 79.93% of US stocks.
  • The strongest trend for ANIX is in Momentum, which has been heading down over the past 31 weeks.
  • ANIX's current lowest rank is in the Quality metric (where it is better than 4.87% of US stocks).

ANIX Stock Summary

  • With a one year PEG ratio of 2,156.01, Anixa Biosciences Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 97.74% of US stocks.
  • For ANIX, its debt to operating expenses ratio is greater than that reported by just 4.57% of US equities we're observing.
  • With a price/sales ratio of 281.09, Anixa Biosciences Inc has a higher such ratio than 98.09% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Anixa Biosciences Inc are VRNS, PFPT, EMX, GDYN, and TYL.
  • Visit ANIX's SEC page to see the company's official filings. To visit the company's web site, go to www.anixa.com.

ANIX Valuation Summary

  • ANIX's EV/EBIT ratio is -10.6; this is 139.7% lower than that of the median Healthcare stock.
  • ANIX's price/sales ratio has moved up 222.7 over the prior 243 months.
  • ANIX's price/sales ratio has moved up 222.7 over the prior 243 months.

Below are key valuation metrics over time for ANIX.

Stock Date P/S P/B P/E EV/EBIT
ANIX 2021-02-11 NA 15.8 -13.8 -13.2
ANIX 2017-08-09 35.7 3.0 -1.9 -3.7
ANIX 2017-07-20 45.3 3.8 -2.4 -4.7
ANIX 2013-01-11 26.5 -41.4 -7.1 -8.1
ANIX 2008-06-23 207.3 6.3 -14.6 -15.2
ANIX 2005-01-26 128.3 33.8 -18.9 -18.6

ANIX Growth Metrics

  • Its 4 year revenue growth rate is now at -100%.
  • Its 2 year net income to common stockholders growth rate is now at -39.18%.
  • Its 3 year net cashflow from operations growth rate is now at -45.98%.
Over the past 34 months, ANIX's revenue has gone down $600,000.

The table below shows ANIX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 0.5125 -5.116963 -9.392861
2020-12-31 0.5125 -5.431713 -9.634103
2020-09-30 0 -6.175671 -10.01835
2020-06-30 0 -6.09863 -9.881813
2020-03-31 0 -5.44779 -9.460157
2019-12-31 0.25 -5.326306 -9.357756

ANIX Price Target

For more insight on analysts targets of ANIX, see our ANIX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.50 Average Broker Recommendation 1.5 (Moderate Buy)

ANIX Stock Price Chart Interactive Chart >

Price chart for ANIX

ANIX Price/Volume Stats

Current price $4.57 52-week high $8.09
Prev. close $4.81 52-week low $1.70
Day low $4.57 Volume 177,300
Day high $4.82 Avg. volume 401,335
50-day MA $4.05 Dividend yield N/A
200-day MA $3.90 Market Cap 136.87M

Anixa Biosciences, Inc. (ANIX) Company Bio


Anixa Biosciences, Inc., a biotechnology company, develops diagnostics and therapeutics to diagnose, treat, and prevent cancer. The company is developing the Cchek platform, a series of non-invasive blood tests for the early detection of cancer, which is based on the body's immune response to the presence of a malignancy. It is also developing a vaccine against triple negative breast cancer; and chimeric endocrine receptor T-cell technology focused on treating ovarian cancer. Anixa Biosciences, Inc. has a collaboration with Urology San Antonio, P.A. and Idaho Urologic Institute, PA for the development of Cchek, a liquid biopsy technology; and with OntoChem GmbH to develop novel Covid-19 therapeutics. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.


ANIX Latest News Stream


Event/Time News Detail
Loading, please wait...

ANIX Latest Social Stream


Loading social stream, please wait...

View Full ANIX Social Stream

Latest ANIX News From Around the Web

Below are the latest news stories about Anixa Biosciences Inc that investors may wish to consider to help them evaluate ANIX as an investment opportunity.

Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | June 12, 2021

Biotech Receives National Cancer Institute Resources Award for Ovarian Cancer Vaccine Program

The award and other recent developments at Anixa Biosciences are covered in an H.C. Wainwright & Co. report.

Streetwise Reports | June 2, 2021

Worldwide Cancer Vaccines Industry to 2026 - Featuring AstraZeneca, GlaxoSmithKline and Moderna Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Cancer Vaccines Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com''s offering. The cancer vaccines market is projected to register a CAGR of 13.24% during the forecast period, with a revenue of approximately USD 4,825.61 million in 2020 and expected to reach USD 10,175.41 million by 2026. Companies Mentioned Anixa Biosciences, Inc. AstraZeneca PLC Bristol Myers Squibb Company F. Hoffmann-La Roche A

Business Wire | June 2, 2021

Anixa Biosciences Announces Support from the National Cancer Institute for Ovarian Cancer Vaccine Developed by Cleveland Clinic

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that its ovarian cancer vaccine technology is part of an award from the National Cancer Institute (NCI).

BioSpace | May 25, 2021

Anixa Biosciences (ANIX) Gets a Buy Rating from H.C. Wainwright

In a report released today, Yi Chen from H.C. The post Anixa Biosciences (ANIX) Gets a Buy Rating from H.C. Wainwright appeared first on Smarter Analyst .

Smarter Analyst | May 21, 2021

Read More 'ANIX' Stories Here

ANIX Price Returns

1-mo 17.78%
3-mo -6.35%
6-mo 25.21%
1-year 60.35%
3-year 38.91%
5-year 43.71%
YTD 48.86%
2020 -6.40%
2019 -16.75%
2018 66.95%
2017 -56.30%
2016 79.40%

Continue Researching ANIX

Here are a few links from around the web to help you further your research on Anixa Biosciences Inc's stock as an investment opportunity:

Anixa Biosciences Inc (ANIX) Stock Price | Nasdaq
Anixa Biosciences Inc (ANIX) Stock Quote, History and News - Yahoo Finance
Anixa Biosciences Inc (ANIX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7473 seconds.